Gabriela Villanueva

Dr. Gabriela Villanueva

Hospital Austral

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GVGabriela Villanueva
Gabriela Villanueva
MGMartin Guscott
Martin Guscott
PSPaula Schaiquevich
Paula Schaiquevich
CSClaudia Sampor
Claudia Sampor
RCRyan Combs
Ryan Combs
SHScott Howard
Scott Howard
Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma that is confined within the CNS. Due to its ability to cross the blood–brain barrier, high-dose methotrexate (HDMTX) is the backbone for induction chemotherapy. This systematic review was conducted to observe outcomes among different HDMTX doses (low, <3 g/m2; intermediate, 3–4.9 g/m2; high, ≥5 g/m2) and regimens used in the treatment of PCNSL. A PubMed search resulted in 26 articles reporting clinical trials using HDMTX for PCNSL, from which 35 treatment cohorts were identified for analysis. The median dose of HDMTX used for induction was 3.5 g/m2 (interquartile range IQR, 3–3.5); the intermediate dose was most frequently used in the studies examined (24 cohorts, 69%). Five cohorts used HDMTX monotherapy, 19 cohorts used HDMTX + polychemotherapy, and 11 cohorts used HDMTX + rituximab ± polychemotherapy. Pooled overall response rate (ORR) estimates for low, intermediate, and high dose HDMTX cohorts were 71%, 76%, and 76%, respectively. Pooled 2-year progression-free survival (PFS) estimates for low, intermediate, and high HDMTX dose cohorts were 50%, 51%, and 55%, respectively. Regimens that included rituximab showed a tendency to have higher ORR and 2-year PFS than those that did not include rituximab. These findings indicate that current protocols utilizing 3–4 g/m2 of HDMTX in combination with rituximab provide therapeutic efficacy in PCNSL.

21 April 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
GVGabriela Villanueva
Gabriela Villanueva
CSClaudia Sampor
Claudia Sampor
FMFlorencia Moreno
Florencia Moreno
DADaniel Alderete
Daniel Alderete
AMAngelica Moresco
Angelica Moresco
GCGuillermo L Chantada
Guillermo L Chantada

20 May 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
GVGabriela Villanueva
Gabriela Villanueva
CSClaudia Sampor
Claudia Sampor
JPJulia Palma
Julia Palma
MVMilena Villarroel
Milena Villarroel
DVDiana Valencia
Diana Valencia
LVLiliana Vasquez
Liliana Vasquez

6 July 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
GCGuillermo L Chantada
Guillermo L Chantada
GVGabriela Villanueva
Gabriela Villanueva
DADavid H. Abramson
David H. Abramson

10 September 2024 in Cancer Medicine
Verified
Journal Article
Open access
NTNicolás Tentoni
Nicolás Tentoni
MHMiriam Hwang
Miriam Hwang
GVGabriela Villanueva
Gabriela Villanueva
RCRyan Combs
Ryan Combs
JLJennifer Lowe
Jennifer Lowe
SHScott C. Howard
Scott C. Howard
Introduction: High‐dose methotrexate (HDMTX) use can be limited by the development of acute kidney injury (AKI). Early AKI detection is paramount to prevent further renal injury and irreversible toxicities. This study sought to determine whether early elimination patterns of MTX would be useful as a biomarker of AKI in HDMTX treatment.Methods: This retrospective cohort study included two sites that collected ≥2 MTX levels within 16 h from completion of MTX infusion. Early levels were tagged and MTX elimination half‐life (t½) were calculated from combinations of two of three different early time periods. Receiver operating characteristic (ROC) curves were synthesized for each elimination t½ (biomarker) with respect to AKI and delayed methotrexate elimination (DME); the biomarker with the highest area under the ROC curve (AUC) was tested in a multiple variable logistic regression model.Results: Data from 169 patients who received a total of 556 courses of HDMTX were analyzed. ROC analysis revealed MTX elimination t½ calculated from the second and third time periods had the highest AUC for AKI at 0.62 (interquartile range [IQR] 0.56–0.69) and DME at 0.86 (IQR 0.73–1.00). After adjusting for age, sex, dose (mg/m2), infusion duration, HDMTX course, and baseline estimated glomerular filtration rate, it remained significant for AKI with an OR of 1.29 and 95% confidence interval of 1.03–1.65.Conclusion: Early MTX elimination t½ measured within 16 h of infusion completion was significantly associated with the development of AKI and serves as an early clearance biomarker that may identify patients who benefit from increased hydration, augmented leucovorin rescue, and glucarpidase administration.

30 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BPBertrand Pourroy
Bertrand Pourroy
MAMaria Dolores Aumente
Maria Dolores Aumente
CKChristian Koenecke
Christian Koenecke
MSMartin Stanulla
Martin Stanulla
AFAndrés José María Ferreri
Andrés José María Ferreri
CRCarmelo Rizzari
Carmelo Rizzari
Objectives: To determine the incidence of delayed methotrexate elimination (DME) and acute kidney injury (AKI) and their associations with clinical outcomes in patients receiving high-dose methotrexate (HDMTX) for cancer treatment. Methods: The HDMTX European Registry collected medical records data from 12 institutions in 5 European countries to investigate the clinical practice patterns of healthcare providers utilizing HDMTX for cancer treatment. Cancer types included were acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL), non-Hodgkin lymphoma (NHL), osteosarcoma, and other CNS cancers. Primary endpoints were the incidence of DME and AKI; secondary endpoints were clinical outcomes, including hospital length of stay (LOS), delay in the subsequent course of treatment, methotrexate dose reduction, and omission of next course of treatment. Associations between the primary and secondary endpoints were analyzed with Chi-square and Wilcoxon rank-sum tests. Results: Among the 2501 total HDMTX courses analyzed, DME occurred in 302 courses (12.1%), and AKI in 384 courses (15.4%). DME incidence was highest in courses for PCNSL (18.2%) and NHL (17.2%); AKI incidence was highest in ALL courses (21.0%). Incidence of DME and AKI varied by age and methotrexate infusion duration among the different cancer types. Occurrence of DME was associated with longer delays prior to the next course of treatment, longer hospital LOS, and more frequent methotrexate dose reductions and dose omissions. Conclusions: While HDMTX is a very effective and safe treatment, administration of efficacious doses of methotrexate can lead to AKI and DME, and no single or combination of patient or treatment factors was found to reliably predict their occurrence. Thus, diligent monitoring of methotrexate levels is imperative for early detection and prompt management of nephrotoxicity in all settings where HDMTX treatment is administered.